An interventional study of Neuspera Implantable Sacral Nerve Stimulation System in Urinary Urgency Incontinence, sponsored by Neuspera Medical, Inc.. Active, not recruiting at 34 sites in 3 countries. Open to participants aged 22 Years and older. Per ClinicalTrials.gov, last updated 2025-11-03.
Sponsored by Neuspera Medical, Inc. · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Prospective, multi-center, single-arm, seamless phase-pivotal study conducted in participants diagnosed with UUI who have failed or could not tolerate more conservative treatment. The trial will be conducted in two phases.
Objective of Phase I: To assess the utilization of the system during the Sacral Nerve Stimulation (SNS) trial period and to help inform the length of hours of daily stimulation to be used in Phase II of the trial.
Objective of Phase II: To assess the safety and efficacy of the Neuspera SNS System at 6-months for the primary efficacy endpoint and at 12 months for secondary safety and efficacy endpoints.
Neuspera's Implantable Sacral Nerve Stimulation (SNS) System is indicated to treat participants with UUI who have failed or could not tolerate more conservative treatments.
The study will be conducted in two phases: Phase I of the study will be conducted at up to 9 clinical study sites in the US and Europe. Phase II of the study will be conducted in up to 35 clinical sites in the US and Europe, inclusive of the Phase I centers.
Prospective, multi-center, single-arm, seamless phase-pivotal study. Objective of Phase I: To assess the utilization of the system during the Sacral Nerve Stimulation (SNS) trial period and to help inform the length of hours of daily stimulation to be used in Phase II of the trial.
Objective of Phase II: To assess the safety and efficacy of the Neuspera SNS System at 6-months for the primary efficacy endpoint and at 12 months for secondary safety and efficacy endpoints. All participants will receive the same length of device stimulation as determined in Phase I testing.
Phase I will enroll up to 55 participants. Phase II will enroll up to 255 participants.
Neuspera Medical, Inc. is the lead sponsor of 5 studies on the registry; 3 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Implantation of the stimulator.
Device: Neuspera Implantable Sacral Nerve Stimulation System
Stimulation of the Sacral Nerve.
Primary Efficacy Endpoint: Percentage of Participants Who Experience a 50 Percent or More Change in Urinary Urgency Incontinence Episodes.
Change in Urinary Urgency Incontinence episodes at six months, relative to the number of Urinary Urgency Incontinence episodes at baseline.
Time frame: 6 months
Primary Safety Endpoint: Defined as the Proportion of Subjects Experiencing a Device-related Serious Adverse Events.
The analysis of the endpoint is the proportion of subjects experiencing a device-related SAE through the 6-month post-implant.
Time frame: 6 months
Phase II Change in Quality of Life: Measured From Baseline as Measured and Assessed by the Total and Subset International Consultation on Incontinence Questionnaire Overactive Bladder Quality of Life Score.
Change from baseline in qualify of life. Total score (25 min,160 max) with higher score indicating increase impact on quality of life.
Time frame: 6 and 12 months
Phase II Efficacy Endpoint: Defined as the Percentage of Participants Who Experience a 50 Percent or More Change in Urinary Urgency Incontinence.
Change in Urinary Urgency Incontinence episodes at 12 months post-completion of the trial phase, relative to the number of Urinary Urgency Incontinence episodes at baseline prior to the trial phase.
Time frame: 12 months
Phase II Urgent Voids Per Day
Change in urgent voids per day from baseline to 6-months and 12 months. Calculated across all diary episodes with at least mild urgency.
Time frame: 6 and 12 months
Phase II Change in Average Number of Daily Voids
Change in average number of daily voids from baseline in subjects with at least 8 voids at baseline.
Time frame: 6 and 12 months
Phase II Comprehensive Summary of All Adverse Events
The incidence of adverse events will be reported.
Time frame: 6 and 12 months
Phase II Device Parameter Information Collected
Device amplitude will be collected in volts.
Time frame: 6 and 12 months
Phase II Physician and Subject User Experience Questionnaire
Physician and subject satisfaction will be obtained by answering questions on the use of the device using a five point scale:strongly agree, agree, neither agree nor disagree, disagree, strongly disagree. Answers towards strongly agree indicate a better outcome.
Time frame: 6 and 12 months
Phase II Urinary Tract Symptoms Questionnaire: International Consultation on Incontinence Questionnaire Female & Male Lower Urinary Tract Symptoms Modules
Change in female lower urinary tract symptoms questionnaire. Male questionnaire score ranges from 0-52 and female questionnaire score ranges from 0-48. Higher number indicates worse outcome.
Time frame: 6 and 12 months
Phase II Safety Endpoint: Defined as the Incidence of Device-related Serious Adverse Events in the Post-trial Period Follow-up.
The number of serious adverse events related to the device.
Time frame: 12 months
Phase II Urinary Output
Total urinary output as measured by 72-hour bladder diary.
Time frame: 6 and 12 months
Phase II Fecal Incontinence Measured by Wexner Scale
Wexner scale total points 0-20, higher the score the worse the outcome. Fecal incontinence as measured by the Wexner Scale compared to baseline.
Time frame: 6 months
Phase II Patient Global Impression of Improvement
Patient Global Impression of Improvement measured after implant during follow-up. Single question answered on a seven point scale: very much better, much better, a little better, no change, a little worse, much worse, very much worse. Selection of very much better is the best outcome.
Time frame: 6 and 12 months
| Milestone | Phase I, Neuspera Implantable Sacral Nerve Stimulation System | Phase II, Neuspera Implantable Sacral Nerve Stimulation System |
|---|---|---|
| Started | 39 | 130 |
| Completed | 34 | 111 |
| Not completed | 5 | 19 |
| Withdrew: Implant attempted but not completed | 5 | 2 |
| Withdrew: Not satisfied with therapy outcome | 0 | 8 |
| Withdrew: Adverse event | 0 | 3 |
| Withdrew: Withdrawal by subject | 0 | 3 |
| Withdrew: Missed visit | 0 | 2 |
| Withdrew: Other reason | 0 | 1 |
Change in Urinary Urgency Incontinence episodes at six months, relative to the number of Urinary Urgency Incontinence episodes at baseline.
| percentage of participants | Phase I, Neuspera Implantable Sacral Nerve Stimulation System | Phase II, Neuspera Implantable Sacral Nerve Stimulation System |
|---|---|---|
| Primary Efficacy Endpoint: Percentage of Participants Who Experience a 50 Percent or More Change in Urinary Urgency Incontinence Episodes. | 93.3 (77.9 to 99.2) | 95.5 (89.8 to 98.5) |
The analysis of the endpoint is the proportion of subjects experiencing a device-related SAE through the 6-month post-implant.
| Participants | Phase I, Neuspera Implantable Sacral Nerve Stimulation System | Phase II, Neuspera Implantable Sacral Nerve Stimulation System |
|---|---|---|
| Primary Safety Endpoint: Defined as the Proportion of Subjects Experiencing a Device-related Serious Adverse Events. | 0 | 0 |
Change from baseline in qualify of life. Total score (25 min,160 max) with higher score indicating increase impact on quality of life.
Results for this outcome have not been posted.
Change in Urinary Urgency Incontinence episodes at 12 months post-completion of the trial phase, relative to the number of Urinary Urgency Incontinence episodes at baseline prior to the trial phase.
Results for this outcome have not been posted.
Change in urgent voids per day from baseline to 6-months and 12 months. Calculated across all diary episodes with at least mild urgency.
Results for this outcome have not been posted.
Change in average number of daily voids from baseline in subjects with at least 8 voids at baseline.
Results for this outcome have not been posted.
The incidence of adverse events will be reported.
Results for this outcome have not been posted.
Device amplitude will be collected in volts.
Results for this outcome have not been posted.
Physician and subject satisfaction will be obtained by answering questions on the use of the device using a five point scale:strongly agree, agree, neither agree nor disagree, disagree, strongly disagree. Answers towards strongly agree indicate a better outcome.
Results for this outcome have not been posted.
Change in female lower urinary tract symptoms questionnaire. Male questionnaire score ranges from 0-52 and female questionnaire score ranges from 0-48. Higher number indicates worse outcome.
Results for this outcome have not been posted.
The number of serious adverse events related to the device.
Results for this outcome have not been posted.
Total urinary output as measured by 72-hour bladder diary.
Results for this outcome have not been posted.
Wexner scale total points 0-20, higher the score the worse the outcome. Fecal incontinence as measured by the Wexner Scale compared to baseline.
Results for this outcome have not been posted.
Patient Global Impression of Improvement measured after implant during follow-up. Single question answered on a seven point scale: very much better, much better, a little better, no change, a little worse, much worse, very much worse. Selection of very much better is the best outcome.
Results for this outcome have not been posted.
Collected over At least 6 months post-implant. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Ph I, Neuspera Implantable Sacral Nerve Stimulation System | 0/39 (0%) | 1/39 (2.6%) | 10/39 (25.6%) |
| Ph II, Neuspera Implantable Sacral Nerve Stimulation System | 0/130 (0%) | 16/130 (12.3%) | 0/130 (0%) |
| Event | Ph I, Neuspera Implantable Sacral Nerve Stimulation System | Ph II, Neuspera Implantable Sacral Nerve Stimulation System |
|---|---|---|
| Numbness and tingling in left footNervous system disorders | 1/39 | 0/130 |
| NephrolithiasisRenal and urinary disorders | 0/39 | 2/130 |
| Abnormal uterine bleedingReproductive system and breast disorders | 0/39 | 2/130 |
| Atrial FibrillationCardiac disorders | 0/39 | 1/130 |
| Intestinal ObstructionGastrointestinal disorders | 0/39 | 1/130 |
| AppendicitisInfections and infestations | 0/39 | 1/130 |
| Breast CellulitisInfections and infestations | 0/39 | 1/130 |
| Ankle FractureInjury, poisoning and procedural complications | 0/39 | 1/130 |
| FallInjury, poisoning and procedural complications | 0/39 | 1/130 |
| Lower Limb FractureInjury, poisoning and procedural complications | 0/39 | 1/130 |
| Event | Ph I, Neuspera Implantable Sacral Nerve Stimulation System | Ph II, Neuspera Implantable Sacral Nerve Stimulation System |
|---|---|---|
| Implant Site PainGeneral disorders | 5/39 | — |
| Device DislocationProduct Issues | 3/39 | — |
| Muscle TightnessMusculoskeletal and connective tissue disorders | 2/39 | — |
| Device BreakageProduct Issues | 2/39 | — |
| Age, Continuous(Years) | Phase I: Neuspera Implantable Sacral Nerve Stimulation System | Phase II: Neuspera Implantable Sacral Nerve Stimulation System | Total |
|---|---|---|---|
| Mean | 59.8 ± 12.6 | 60.4 ± 10.2 | 60.2 ± 10.8 |
| Sex: Female, Male(Participants) | Phase I: Neuspera Implantable Sacral Nerve Stimulation System | Phase II: Neuspera Implantable Sacral Nerve Stimulation System | Total |
|---|---|---|---|
| Female | 37 | 128 | 165 |
| Male | 2 | 2 | 4 |
| Ethnicity (NIH/OMB)(Participants) | Phase I: Neuspera Implantable Sacral Nerve Stimulation System | Phase II: Neuspera Implantable Sacral Nerve Stimulation System | Total |
|---|---|---|---|
| Hispanic or Latino | 1 | 10 | 11 |
| Not Hispanic or Latino | 38 | 120 | 158 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Phase I: Neuspera Implantable Sacral Nerve Stimulation System | Phase II: Neuspera Implantable Sacral Nerve Stimulation System | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 1 | 5 | 6 |
| White | 38 | 124 | 162 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 1 | 1 |
| Body Mass Index (BMI)(kg/m2) | Phase I: Neuspera Implantable Sacral Nerve Stimulation System | Phase II: Neuspera Implantable Sacral Nerve Stimulation System | Total |
|---|---|---|---|
| Mean | 30 ± 5.4 | 29.5 ± 5.1 | 29.6 ± 5.2 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No — At this time, there is no plan to share information.
Ran from Dec 2019 to primary completion in Jul 2024, 55 months.
Results were first posted in Nov 2025, 1 year 3 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Oct 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Neuspera Medical, Inc.